Credit-Canva
Many people believe that the modern-day skincare trends are a scam made by the big pharma companies who wish to make more money. This is a recent trend of ‘Anti-Aging’ skincare that keeps yourself on toes for the innate need for women to stay ‘young’ if they wish to be desirable. The beauty industry, in a way, feeds on such societal-made insecurities. But the recent rise in the trend has taken a different turn. While before people did it before to look prettier or fairer, now people are looking at this skincare routine as a way of taking care of themselves rather than doing to match someone else's beauty standards. This is why, this trend has resurfaced in the skin care community. This is the blue light routine.
In today's digital age, where we spend countless hours looking at screens, from phones and tablets to laptops. This constant screen time exposes us to blue light, which research suggests can have negative effects on our skin. It also leads to premature aging and dark spots. The screens also leads to stress, which could further cause harm to skin. While ditching our devices isn't realistic, a growing number of skincare products claim to protect against blue light. But do these products actually work?
You can find many skincare products that say they protect against blue light, like sprays, creams, gels, and sunscreens. Some promise to undo the damage blue light might cause, while others try to prevent it in the first place. Blue light sunscreens are special because they protect against both the sun's UV rays and blue light. This is what regular sunscreens don't do very well. Regular sunscreens, whether they use chemicals or minerals, don't block blue light as effectively.
However, tinted sunscreens are different. Tinted sunscreens with SPF 30 or higher can protect your skin from blue light, as well as UVA and UVB rays from the sun. This is because of the coloring in the tint. Some newer sunscreens also have special ingredients that help protect against visible light, including blue light. While scientists are still learning about how blue light affects skin, many skin doctors have found it to be helpful for skin.
Blue light comes from screens, TVs, and even the sun. While we used to worry mostly about how it affects our eyes and sleep, now we're learning it might also affect our skin. Some studies show that too much blue light can damage skin cells and speed up aging, leading to wrinkles and uneven skin tone. It can also cause dark spots on the skin. This happens because blue light can cause something called "oxidative stress" in the skin, which is linked to aging. It leads to dead skin cells. Blue light goes deeper into the skin than the sun's UV rays and can make skin cells produce more pigment, causing dark spots. It's important to know that not all blue light is bad. There is a difference between the blue light that comes out of the screens and the blue light that is used from a certain blue light wavelength as a therapy. The latter is used by doctors to treat acne and some skin cancers.
Credits: canva
A woman experiencing abdominal discomfort went to her gynecologist for an ultrasound, only to discover something far more startling than a baby. The mom, who shares her story on TikTok under the handle @sandwitchbread, revealed her medical surprise in a video that has now amassed over 1.9 million views. She said she had been struggling with pain and unusual bleeding since giving birth to her two-year-old son and decided to see a gynecologist fearing she might be pregnant again.
During the ultrasound, she noticed something on the screen, but the doctor quickly reassured her it wasn’t a baby. “When my doctor came in to share the results,” the TikToker recalled, “she looked me in the eyes and told me I had a seven-centimeter cyst, about the size of a chicken egg, called a dermoid cyst.”
A dermoid cyst is a pocket of tissue growth that can contain normal body tissues, sometimes including hair, fluid, teeth, or skin. While this TikToker’s cyst was in her uterus, dermoid cysts are most commonly found in the ovaries. They are generally harmless but often require surgical removal. According to the National Cancer Institute, dermoid cysts are present from birth but may not be detected until later in life. These benign tumors originate from embryonic cells that become “trapped” and develop into tissues in the wrong location. Teeth and hair are frequent components, and surgery is usually recommended if the cyst causes symptoms or complications.
Dermoid cysts develop hair and teeth because they arise from trapped embryonic cells (ectoderm) that can grow into skin, hair follicles, sweat glands, and even teeth, instead of forming the tissues normally found in the ovary or skin. Essentially, they are benign tumors made up of mature but misplaced body tissues from the outer layer of the embryo, which normally forms skin and related structures.
Most ovarian dermoid cysts remain symptom-free unless complications occur. When symptoms do appear, the most common one reported is lower abdominal pain.
As the cyst enlarges, it can cause noticeable abdominal swelling and problems with the urinary or digestive system.
In more severe cases, individuals might also experience:
The Office on Women’s Health notes that cysts on the ovaries can also cause:
Some potential complications include:
Rupturing of the cyst: Though rare, ovarian dermoid cysts can burst. If the cyst’s contents leak into the abdominal cavity, it may lead to chronic inflammation of the abdominal lining (peritonitis). In some cases, leakage into the intestines or rectum can result in the material being expelled through the anus.
Ovarian torsion: This occurs when the cyst twists the ligaments holding the ovary in place, which can cut off blood supply to the ovary and fallopian tube.
Infection: The risk of infection is around 1–4%. Severe infections may lead to cyst rupture.
Malignant transformation: Dermoid cysts are almost always benign, but in rare instances, they can become cancerous.
Credits: Canva
A new weight-loss drug often described as the “triple G” treatment because it mimics three hormones linked to hunger and metabolism has delivered striking results in fresh data shared Thursday by its developer, Eli Lilly. In a clinical study involving more than 400 people living with obesity and knee osteoarthritis, the experimental drug retatrutide led to an average weight reduction of 71 pounds, or close to 29% of total body weight, over a period of 16 months, according to figures released by the company. Participants who received retatrutide also reported a 76% drop in knee pain by the end of the study period, based on the same data. So is
Retatrutide is an experimental weight-loss drug developed by Eli Lilly and is widely seen as a next-step advancement beyond current GLP-1-based medications such as semaglutide and tirzepatide. While semaglutide acts on a single hormone pathway and tirzepatide works on two, retatrutide targets three.
It activates GLP-1 and GIP, along with an added glucagon pathway, which is why it is sometimes informally referred to as a “GLP-3” drug. Researchers believe this third pathway could explain the greater weight-loss effects seen so far, although retatrutide remains under investigation and has not yet received FDA approval.
Even without regulatory approval, retatrutide has gained attention among gym enthusiasts, fitness creators, and online weight-loss communities. On platforms like TikTok, where direct searches for #reta or #retatrutide are restricted, users often refer to it using coded terms such as “ratatouille.”
At the same time, the drug has been in the news due to growing concerns about counterfeit versions. Reports from the UK recently revealed that authorities seized more than £250,000 worth of fake weight-loss injection pens labelled as tirzepatide and retatrutide from a hidden factory in Northampton. These products are especially concerning because retatrutide is still in clinical trials and has not been approved for use anywhere in the world.
Retatrutide works by mimicking three hormones that play a role in appetite and metabolism: GLP-1, GIP, and glucagon. In contrast, most weight-loss drugs currently available target only one or two of these pathways. Ozempic and Wegovy, made by Novo Nordisk, copy the effects of GLP-1, a hormone that influences the brain, pancreas, stomach, liver, and muscles, according to the National Institutes of Health.
Mounjaro and Zepbound, on the other hand, act on both GLP-1 and GIP, a hormone involved in blood sugar regulation through insulin stimulation. Retatrutide’s added glucagon effect is key, as glucagon is known to support fat burning, even when the body is at rest. Ozempic and Mounjaro are approved by the FDA for treating Type 2 diabetes, while Wegovy and Zepbound are approved for people with overweight or obesity. As with any prescription drug, it is important for individuals to consult a healthcare professional to determine whether these treatments are appropriate for them.
There is currently no confirmed timeline for when retatrutide might become available by prescription. Its launch will depend on the FDA’s detailed evaluation of clinical trial data once it is formally submitted. Based on current expectations, approval is unlikely before late 2026 and could potentially extend into 2027 or even 2028.
Credits: Canva
The use of nicotine pouches is rising sharply across the UK, especially among young adults, recent research suggests. These small pouches sit between the lip and gum and release nicotine gradually into the body. Available in many flavours, they often include sweeteners and plant-based fibres. But are they truly a better option than smoking, or could nicotine pouches still pose health risks? We take a closer look below.
Nicotine pouches are small, tobacco-free sachets that contain nicotine powder along with flavourings and fillers. They are placed between the lip and gum, similar to snus, allowing nicotine to be absorbed without smoke, vapour, or spitting. Marketed as a discreet way to consume nicotine, they still deliver a highly addictive substance and expose users to certain chemicals. Health experts have raised concerns, particularly for young people, despite these products often being promoted as a “safer” choice than cigarettes.
Popular brands such as Zyn, On!, and Velo now dominate a fast-growing market, according to the CDC. Like vaping, they do not contain tobacco and are generally viewed as less harmful than smoking.
A recent study led by researchers at University College London (UCL) found that over the past five years, about 522,000 additional people in the UK have started using nicotine pouches, with usage rising from 0.1% to 1% of the adult population.
This has raised an important question: are nicotine pouches actually safer than smoking, and what is driving their sudden popularity?
Speaking on *Mornings with Ridge and Frost*, lead study author Dr Harry Tattan-Birch from UCL’s Institute of Epidemiology and Health Care told Sky News that the risks linked to nicotine pouches are much lower than those associated with smoking. “There’s no tobacco and no combustion,” he explained. “And we know it’s the burning of tobacco that causes most smoking-related diseases.”
That said, Dr Tattan-Birch and his colleagues stressed that these products are not harmless and should never be accessible to children. The NHS notes that while nicotine itself does not cause serious diseases in the way tobacco does, young people’s developing brains and lungs are more vulnerable to its effects, and dependency can form quickly.
UCL research fellow Eve Taylor also told Sky News that nicotine pouches are “far less harmful than smoking,” but cautioned that they are still relatively new. Because of this, their long-term effects are not yet fully understood. “We can look at what’s in them to estimate potential risks,” she said. “They’re not risk-free. Users are still exposed to some toxic substances, even if the levels are much lower.”
According to UCL’s findings, among participants surveyed between January 2022 and March 2025, 69% of nicotine pouch users were also using other nicotine products. More than half of them, 56%, were still smoking cigarettes. Around one in six users, or 16%, reported that they had never been regular smokers, suggesting the habit was not linked to quitting cigarettes.
As quoted by Sky News, Dr Tattan-Birch said the public health impact of nicotine pouches depends largely on who is using them. “If a young person who might otherwise smoke switches to pouches, that could reduce harm,” he said. “But if someone who wouldn’t have used nicotine at all starts using them, the risk of harm goes up.”
Researchers added that more studies are needed to understand whether nicotine pouches genuinely help people stop smoking in the long run.
Nicotine patches are widely regarded as safer than smoking and are a well-established aid for quitting. They provide a steady dose of nicotine to reduce cravings without exposing users to tar or cancer-causing chemicals found in cigarettes. However, they are not completely without side effects. Common issues include skin irritation, headaches, and sleep disturbances. People with serious heart conditions or those who are pregnant are advised to speak with a doctor before using them, as nicotine can still affect heart rate and blood pressure, though far less dangerously than smoking, according to the CDC.
© 2024 Bennett, Coleman & Company Limited